Consulting fees

X__None

4

Yichao Ma

Ma	anuscript Title: <u>Identificatio</u> i	n of the clinical prediction i	model and biomarkers based on chromatin regulators in	colon
cai	ncer by integrated analysis o	of bulk- and single-cell RNA	sequencing data	
Ma	anuscript number (if known)	: TCR-23-1886		
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" mea e affected by the content on necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	e following questions apply anuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hyperte edication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reporte	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other iter	9
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
L	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	36 months	
)	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
}	Royalties or licenses	X_None		

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	· ·	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and or traver		
8	Patents planned, issued or	X None	
0	pending	XNone	
	pending		
	5 5 .		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Cook or cook operand		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	Nana		
	None.		

Date: <u>Dec. 6th, 2023</u>								
Your Name: $\frac{\cancel{50}}{\cancel{50}}$ Fang Fang								
Manuscript Title: Identification of th	Manuscript Title: Identification of the clinical prediction model and biomarkers based on chromatin regulators in colon							
cancer by integrated analysis of bulk	- and single-cell RNA sequencing data							
Manuscript number (if known): TCR	-23-1886							
•	sk you to disclose all relationships/activities/interests listed below that are							
•	script. "Related" means any relation with for-profit or not-for-profit third							
•	ted by the content of the manuscript. Disclosure represents a commitment							
to transparency and does not necess	arily indicate a bias. If you are in doubt about whether to list a							

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	· ·	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and or traver		
8	Patents planned, issued or	X None	
0	pending	XNone	
	pending		
	5 5 .		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Cook or cook operand		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	Nana		
	None.		

Date: <u>Dec. 6th, 2023</u>

Consulting fees

X__None

4

Kai Liao

Yo	ur Name: <u> </u>	i Liao				
Ma	anuscript Title: <u>Identificatior</u>	n of the clinical prediction i	model and biomarkers based on chromatin regulators in	colon		
ca	cancer by integrated analysis of bulk- and single-cell RNA sequencing data					
Ma	anuscript number (if known)	: TCR-23-1886				
In rel pa to rel Th ma	the interest of transparency ated to the content of your rties whose interests may be transparency and does not rationship/activity/interest, e following questions apply anuscript only. e author's relationships/activite epidemiology of hypertedication, even if that medicated the epidemiology of the epidemiology of that medicated in the epidemiology of the epidemiology of that medicated in the epidemiology of the epidemiol	we ask you to disclose all manuscript. "Related" mea e affected by the content of necessarily indicate a bias. It is preferable that you do to the author's relationship in the serion, you should declare eation is not mentioned in the poort for the work reported.	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertain all relationships with manufacturers of antihypertensive	e		
		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)			
			planning of the work			
L	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone				
		Time frame: past	36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None				
3	Royalties or licenses	XNone				

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	· ·	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and or traver		
8	Patents planned, issued or	X None	
0	pending	XNone	
	pending		
	5 5 .		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Cook or cook operand		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	Nana		
	None.		

Manuscript Title: Identification of the clinical prediction model and biomarkers based on chromatin regulators in colon

Jingqiu Zhang

cancer by integrated analysis of bulk- and single-cell RNA sequencing data

X__None

Date: <u>Dec. 6th, 2023</u>

Consulting fees

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below to related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit parties whose interests may be affected by the content of the manuscript. Disclosure represents a comm to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the curremanuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihyp medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all of the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Time frame: past 36 months Time frame: past 36 months A None Time frame: past 36 months	Ma	anuscript number (if known): TCR-23-1886				
manuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihype medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all of the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Time frame: past 36 months	rela par to t	ated to the content of your ties whose interests may be cransparency and does not i	manuscript. "Related" me e affected by the content necessarily indicate a bias	eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a		
to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihyp medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all of the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Time frame: past 36 months Time frame: past 36 months			to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>		
whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Time frame: past 36 months X_None	to t me In i	the epidemiology of hypertodication, even if that medicatem #1 below, report all su	ension, you should declare ation is not mentioned in pport for the work reporte	e all relationships with manufacturers of antihypertensive the manuscript.		
Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Grants or contracts from any entity (if not indicated in item #1 above).			whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your		
manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Grants or contracts from any entity (if not indicated in item #1 above).				al planning of the work		
Grants or contracts fromX_None any entity (if not indicated in item #1 above).	L	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	XNone			
any entity (if not indicated in item #1 above).			Time frame: pas	t 36 months		
Royalties or licensesX_None	2	any entity (if not indicated	XNone			
	3	Royalties or licenses	XNone			

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	· · ·	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and or traver		
8	Patents planned, issued or	X None	
0	pending	XNone	
	pending		
	5 5 .		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Cook or cook operand		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	Nana		
	None.		

Date: <u>Dec. 6th, 2023</u>

Consulting fees

X__None

4

Yo	our Name: <u>‡ ‰ Che</u>	en Wei	
M	anuscript Title: <u>Identificatio</u> i	n of the clinical prediction	model and biomarkers based on chromatin regulators in colon
<u>ca</u>	ncer by integrated analysis c	of bulk- and single-cell RNA	A sequencing data
M	anuscript number (if known)	: TCR-23-1886	
re pa to	lated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content on necessarily indicate a bias.	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.
	e following questions apply anuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>
to m	the epidemiology of hyperte edication, even if that medic	ension, you should declare ation is not mentioned in	
	item #1 below, report all su e time frame for disclosure i	• •	ed in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
	Royalties or licenses	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	· · ·	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and or traver		
8	Patents planned, issued or	X None	
0	pending	XNone	
	pending		
	5 5 .		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Cook or cook operand		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	Nana		
	None.		

Manuscript Title: Identification of the clinical prediction model and biomarkers based on chromatin regulators in colon

Date: <u>Dec. 6th, 2023</u> Your Name: **Y

Consulting fees

Yiqun Liao

Manuscript number (if known): TCR-23-1886

cancer by integrated analysis of bulk- and single-cell RNA sequencing data

X__None

rel pa to rel Th ma Th to me	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only. e author's relationships/act the epidemiology of hypertedication, even if that medication, even if that medicated item #1 below, report all support and support support and support support and support s	manuscript. "Related" mee affected by the content of the author's relationsh divities/interests should be ension, you should declare that it is not mentioned in a poort for the work reported.	ips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive
the	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	· · ·	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and or traver		
8	Patents planned, issued or	X None	
0	pending	XNone	
	pending		
	5 5 .		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Cook or cook operand		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	Nana		
	None.		

Date: <u>Dec. 6th, 2023</u>

Consulting fees

X__None

4

Bin Zhao

Yo	ur Name: 🖢 🙀 💮 Bin Z	hao		
Ma	anuscript Title: <u>Identificatio</u>	n of the clinical prediction	model and biomarkers based on chromatin regulators in colo	<u>n</u>
	ncer by integrated analysis of anuscript number (if known)	=	A sequencing data	
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.	
	e following questions apply anuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hypertoedication, even if that medic	ension, you should declare ation is not mentioned in pport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items,	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	al planning of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: pas	t 36 months	
<u>)</u>	Grants or contracts from any entity (if not indicated in item #1 above).	X_None		
}	Royalties or licenses	XNone		

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	· · ·	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and or traver		
8	Patents planned, issued or	X None	
0	pending	XNone	
	pending		
	5 5 .		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Cook or cook operand		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	Nana		
	None.		

Manuscript Title: Identification of the clinical prediction model and biomarkers based on chromatin regulators in colon

Date: <u>Dec. 6th, 2023</u>

Your Name: _______

4

Consulting fees

X None

Yongkun Fang

	ncer by integrated analysis on nuscript number (if known)	-	A sequencing data
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a o so.
	e following questions apply inuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>
to		ension, you should declare	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.
	item #1 below, report all su e time frame for disclosure i		ed in this manuscript without time limit. For all other items
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
-	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
)	Grants or contracts from any entity (if not indicated	Time frame: pas	t 36 months
3	in item #1 above). Royalties or licenses	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	· · ·	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and or traver		
8	Patents planned, issued or	X None	
0	pending	XNone	
	pending		
	5 5 .		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Cook or cook operand		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	Nana		
	None.		

Date: <u>Dec. 6th, 2023</u>
Your Name:Yuji Chen
Manuscript Title: Identification of the clinical prediction model and biomarkers based on chromatin regulators in colon
cancer by integrated analysis of bulk- and single-cell RNA sequencing data
Manuscript number (if known): TCR-23-1886
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> .
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	· ·	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and or traver		
8	Patents planned, issued or	X None	
0	pending	XNone	
	pending		
	5 5 .		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Cook or cook operand		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	Nana		
	None.		

Grants or contracts from

in item #1 above). Royalties or licenses

Consulting fees

any entity (if not indicated

2

3

4

Dat	te: <u>Dec. 6th, 2023</u>					
You	ur Name: <u>巻号巻 Xir</u>	nyue Zhang				
Ma	nuscript Title: Identification	n of the clinical prediction	<u>model and biomarkers based on chromatin regulators i</u>	<u>n colon</u>		
<u>car</u>	<u>icer by integrated analysis c</u>	of bulk- and single-cell RNA	sequencing data			
Ma	nuscript number (if known)	: TCR-23-1886				
rela par to t	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.					
	e following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>			
to to to me	the epidemiology of hypertodication, even if that medic	ension, you should declare ation is not mentioned in to pport for the work reporte	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertensi the manuscript. d in this manuscript without time limit. For all other it	ve		
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)			
		needed) Time frame: Since the initial	nlanning of the work			
		Time frame. Since the initial	planning of the work			
L	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone				
	processing charges, etc.) No time limit for this item.					

Time frame: past 36 months

X__None

X__None

X__None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	· ·	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
	meetings and or traver		
8	Patents planned, issued or	X None	
0	pending	XNone	
	pending		
	5 5 .		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Cook or cook operand		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	Nana		
	None.		

Date: <u>Dec. 6th, 2023</u>

Consulting fees

X__None

4

Yo	ur Name: <u>公</u> 集 Don	ng Tang		
	•	n of the clinical prediction	model and biomarkers based on chromatin regulators in colo	<u>on</u>
ca	ncer by integrated analysis o	of bulk- and single-cell RNA	sequencing data	
Ma	anuscript number (if known)	: TCR-23-1886		
rel pa to rel	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest,	manuscript. "Related" mea e affected by the content on necessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so. ps/activities/interests as they relate to the current	
to me	the epidemiology of hyperto edication, even if that medic	ension, you should declare ation is not mentioned in t pport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items,	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
l	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	26 months	
)	Grants or contracts from any entity (if not indicated	XNone		
	in item #1 above).	V N		
3	Royalties or licenses	XNone		

5 Payment or honoraria for Lectures, presentations, speakers bureaus,	
speakers bureaus	
manuscript writing or educational events	
6 Payment for expertX_None	
testimony	
testimony	
7 Support for attendingXNone	
meetings and/or travel	
8 Patents planned, issued orXNone	
pending	
9 Participation on a DataXNone	
Safety Monitoring Board or	
Advisory Board	
10 Leadership or fiduciary roleX_None	
in other board, society,	
committee or advocacy	
group, paid or unpaid	
11 Stock or stock options X_None	
42 Paralist of audiencest V Name	
12 Receipt of equipment,X_None	
writing, gifts or other	
services	
13 Other financial or non- financial interests X_None	
Thrulled interests	
Please summarize the above conflict of interest in the following box:	
None.	